JPH11507201A - 筋肉の疾患および障害の治療方法 - Google Patents
筋肉の疾患および障害の治療方法Info
- Publication number
- JPH11507201A JPH11507201A JP6525593A JP52559394A JPH11507201A JP H11507201 A JPH11507201 A JP H11507201A JP 6525593 A JP6525593 A JP 6525593A JP 52559394 A JP52559394 A JP 52559394A JP H11507201 A JPH11507201 A JP H11507201A
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- polypeptide
- muscle
- cells
- muscle cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 181
- 208000029578 Muscle disease Diseases 0.000 title claims description 11
- 208000021642 Muscular disease Diseases 0.000 title claims description 11
- 210000003205 muscle Anatomy 0.000 claims abstract description 76
- 150000001875 compounds Chemical class 0.000 claims abstract description 39
- 230000001965 increasing effect Effects 0.000 claims abstract description 25
- 210000002460 smooth muscle Anatomy 0.000 claims abstract description 6
- 210000002027 skeletal muscle Anatomy 0.000 claims abstract description 5
- 230000000747 cardiac effect Effects 0.000 claims abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 184
- 210000004027 cell Anatomy 0.000 claims description 180
- 108090000623 proteins and genes Proteins 0.000 claims description 129
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 124
- 229920001184 polypeptide Polymers 0.000 claims description 106
- 210000000663 muscle cell Anatomy 0.000 claims description 79
- 239000003814 drug Substances 0.000 claims description 60
- 241000283690 Bos taurus Species 0.000 claims description 50
- 238000011282 treatment Methods 0.000 claims description 49
- 238000004519 manufacturing process Methods 0.000 claims description 36
- 230000002297 mitogenic effect Effects 0.000 claims description 32
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 29
- 210000003098 myoblast Anatomy 0.000 claims description 28
- 210000000107 myocyte Anatomy 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 230000014509 gene expression Effects 0.000 claims description 20
- 210000001087 myotubule Anatomy 0.000 claims description 20
- 102000005962 receptors Human genes 0.000 claims description 19
- 108020003175 receptors Proteins 0.000 claims description 19
- 230000015572 biosynthetic process Effects 0.000 claims description 18
- 230000027455 binding Effects 0.000 claims description 15
- 239000003226 mitogen Substances 0.000 claims description 15
- 102000034337 acetylcholine receptors Human genes 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 13
- 238000003786 synthesis reaction Methods 0.000 claims description 13
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 11
- 210000002950 fibroblast Anatomy 0.000 claims description 11
- 230000004936 stimulating effect Effects 0.000 claims description 10
- 230000006378 damage Effects 0.000 claims description 9
- 208000013363 skeletal muscle disease Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 8
- 230000004663 cell proliferation Effects 0.000 claims description 7
- 230000022379 skeletal muscle tissue development Effects 0.000 claims description 6
- 206010003694 Atrophy Diseases 0.000 claims description 5
- 230000037444 atrophy Effects 0.000 claims description 5
- 210000000481 breast Anatomy 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 230000037257 muscle growth Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 208000029549 Muscle injury Diseases 0.000 claims description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 239000003900 neurotrophic factor Substances 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 208000019553 vascular disease Diseases 0.000 claims description 4
- 102100035680 Cadherin EGF LAG seven-pass G-type receptor 2 Human genes 0.000 claims description 3
- 102100035671 Cadherin EGF LAG seven-pass G-type receptor 3 Human genes 0.000 claims description 3
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 3
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 3
- 102100032029 Epidermal growth factor-like protein 6 Human genes 0.000 claims description 3
- 101000715674 Homo sapiens Cadherin EGF LAG seven-pass G-type receptor 2 Proteins 0.000 claims description 3
- 101000715671 Homo sapiens Cadherin EGF LAG seven-pass G-type receptor 3 Proteins 0.000 claims description 3
- 101000921196 Homo sapiens Epidermal growth factor-like protein 6 Proteins 0.000 claims description 3
- 101000955263 Homo sapiens Multiple epidermal growth factor-like domains protein 6 Proteins 0.000 claims description 3
- 101000955249 Homo sapiens Multiple epidermal growth factor-like domains protein 8 Proteins 0.000 claims description 3
- 101000955254 Homo sapiens Multiple epidermal growth factor-like domains protein 9 Proteins 0.000 claims description 3
- 102100039005 Multiple epidermal growth factor-like domains protein 6 Human genes 0.000 claims description 3
- 102100038990 Multiple epidermal growth factor-like domains protein 8 Human genes 0.000 claims description 3
- 102100038989 Multiple epidermal growth factor-like domains protein 9 Human genes 0.000 claims description 3
- 201000009623 Myopathy Diseases 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- 208000028389 Nerve injury Diseases 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 230000009756 muscle regeneration Effects 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 230000008764 nerve damage Effects 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 208000020446 Cardiac disease Diseases 0.000 claims 4
- 208000019622 heart disease Diseases 0.000 claims 4
- 230000002708 enhancing effect Effects 0.000 claims 3
- 230000002463 transducing effect Effects 0.000 claims 2
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 claims 1
- 208000021908 Myocardial disease Diseases 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 208000017708 myomatous neoplasm Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 208000024335 physical disease Diseases 0.000 claims 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 abstract description 34
- 230000004083 survival effect Effects 0.000 abstract description 28
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract description 7
- 210000004165 myocardium Anatomy 0.000 abstract description 5
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract description 2
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 description 96
- 235000018102 proteins Nutrition 0.000 description 94
- 108090000556 Neuregulin-1 Proteins 0.000 description 90
- 102000048238 Neuregulin-1 Human genes 0.000 description 83
- 108020004635 Complementary DNA Proteins 0.000 description 69
- 150000001413 amino acids Chemical class 0.000 description 51
- 230000000694 effects Effects 0.000 description 49
- 239000000523 sample Substances 0.000 description 42
- 239000002299 complementary DNA Substances 0.000 description 37
- 239000002609 medium Substances 0.000 description 35
- 239000000047 product Substances 0.000 description 33
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 32
- 210000004116 schwann cell Anatomy 0.000 description 32
- 239000003636 conditioned culture medium Substances 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 27
- 239000002773 nucleotide Substances 0.000 description 25
- 238000003556 assay Methods 0.000 description 24
- 125000003729 nucleotide group Chemical group 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 23
- 238000003752 polymerase chain reaction Methods 0.000 description 21
- 229940024606 amino acid Drugs 0.000 description 19
- 239000013615 primer Substances 0.000 description 19
- 239000013598 vector Substances 0.000 description 19
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 101100226904 Unknown prokaryotic organism FCS1 gene Proteins 0.000 description 17
- 238000000746 purification Methods 0.000 description 17
- 239000000872 buffer Substances 0.000 description 16
- 239000000499 gel Substances 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- 238000009396 hybridization Methods 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 239000000854 Human Growth Hormone Substances 0.000 description 14
- 108010029485 Protein Isoforms Proteins 0.000 description 14
- 102000001708 Protein Isoforms Human genes 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 102000002265 Human Growth Hormone Human genes 0.000 description 13
- 108010000521 Human Growth Hormone Proteins 0.000 description 13
- 108050003475 Neuregulin Proteins 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 102000014413 Neuregulin Human genes 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 230000035755 proliferation Effects 0.000 description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 11
- 239000003102 growth factor Substances 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 230000001817 pituitary effect Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 10
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 9
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 9
- 238000010367 cloning Methods 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 239000002751 oligonucleotide probe Substances 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 8
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 8
- 102400000058 Neuregulin-1 Human genes 0.000 description 8
- 101800002648 Neuregulin-1 Proteins 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 231100000673 dose–response relationship Toxicity 0.000 description 8
- 239000000835 fiber Substances 0.000 description 8
- 238000010348 incorporation Methods 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- -1 nasal solution Substances 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000006820 DNA synthesis Effects 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 244000309466 calf Species 0.000 description 7
- 238000001516 cell proliferation assay Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 108700024394 Exon Proteins 0.000 description 6
- 101001109800 Homo sapiens Pro-neuregulin-1, membrane-bound isoform Proteins 0.000 description 6
- 206010028289 Muscle atrophy Diseases 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 6
- 238000012300 Sequence Analysis Methods 0.000 description 6
- 239000013553 cell monolayer Substances 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 230000002518 glial effect Effects 0.000 description 6
- 102000055650 human NRG1 Human genes 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000004498 neuroglial cell Anatomy 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 230000008929 regeneration Effects 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 108091033380 Coding strand Proteins 0.000 description 5
- 239000003298 DNA probe Substances 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 238000002105 Southern blotting Methods 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 238000000376 autoradiography Methods 0.000 description 5
- 238000005341 cation exchange Methods 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000032823 cell division Effects 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 230000008747 mitogenic response Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000008488 polyadenylation Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 108020003215 DNA Probes Proteins 0.000 description 4
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 102000013415 peroxidase activity proteins Human genes 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 238000010599 BrdU assay Methods 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000004988 N-glycosylation Effects 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 3
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102100038126 Tenascin Human genes 0.000 description 3
- 108010008125 Tenascin Proteins 0.000 description 3
- 102000013127 Vimentin Human genes 0.000 description 3
- 108010065472 Vimentin Proteins 0.000 description 3
- 108010006886 Vitrogen Proteins 0.000 description 3
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 238000009650 gentamicin protection assay Methods 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 108010034429 heregulin alpha Proteins 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 208000015357 muscle tissue disease Diseases 0.000 description 3
- 201000000585 muscular atrophy Diseases 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 210000005048 vimentin Anatomy 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101000783401 Bungarus multicinctus Alpha-bungarotoxin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 108010069091 Dystrophin Proteins 0.000 description 2
- 102000001039 Dystrophin Human genes 0.000 description 2
- 102000012545 EGF-like domains Human genes 0.000 description 2
- 108050002150 EGF-like domains Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 2
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 2
- 241001553014 Myrsine salicina Species 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000008049 TAE buffer Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 230000004992 fission Effects 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 229940116978 human epidermal growth factor Drugs 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000030214 innervation Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 108010046018 leukocyte inhibitory factor Proteins 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- 230000001114 myogenic effect Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 210000000715 neuromuscular junction Anatomy 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 239000012521 purified sample Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
- 229940048086 sodium pyrophosphate Drugs 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- YCYMCMYLORLIJX-SNVBAGLBSA-N (2r)-2-propyloctanoic acid Chemical compound CCCCCC[C@H](C(O)=O)CCC YCYMCMYLORLIJX-SNVBAGLBSA-N 0.000 description 1
- LINMATFDVHBYOS-MBJXGIAVSA-N (2s,3r,4s,5r,6r)-2-[(5-bromo-1h-indol-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C=C12 LINMATFDVHBYOS-MBJXGIAVSA-N 0.000 description 1
- PQMRRAQXKWFYQN-UHFFFAOYSA-N 1-phenyl-2-sulfanylideneimidazolidin-4-one Chemical compound S=C1NC(=O)CN1C1=CC=CC=C1 PQMRRAQXKWFYQN-UHFFFAOYSA-N 0.000 description 1
- KDELTXNPUXUBMU-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid boric acid Chemical compound OB(O)O.OB(O)O.OB(O)O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KDELTXNPUXUBMU-UHFFFAOYSA-N 0.000 description 1
- KFHRMMHGGBCRIV-UHFFFAOYSA-N 2-azaniumyl-4-methoxybutanoate Chemical compound COCCC(N)C(O)=O KFHRMMHGGBCRIV-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 101710195183 Alpha-bungarotoxin Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101150102965 B2 gene Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101710081103 Cuticular glutathione peroxidase Proteins 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 241000617590 Escherichia coli K1 Species 0.000 description 1
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 102100032864 General transcription factor IIH subunit 2 Human genes 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 101710099093 Growth hormone receptor Proteins 0.000 description 1
- 108010027814 HSP72 Heat-Shock Proteins Proteins 0.000 description 1
- 102100040352 Heat shock 70 kDa protein 1A Human genes 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 102100037907 High mobility group protein B1 Human genes 0.000 description 1
- 101710168537 High mobility group protein B1 Proteins 0.000 description 1
- 102100022128 High mobility group protein B2 Human genes 0.000 description 1
- 101710168540 High mobility group protein B2 Proteins 0.000 description 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 241000209027 Ilex aquifolium Species 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 108010053229 Lysyl endopeptidase Proteins 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 101100384399 Mus musculus C2 gene Proteins 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 101800000135 N-terminal protein Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101800001452 P1 proteinase Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 238000003684 Perkin reaction Methods 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- 101150100857 RIOX2 gene Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 1
- 108020000715 acetylcholine receptors Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000003352 adrenal gland pheochromocytoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 108010066058 beta Subunit Luteinizing Hormone Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000036782 biological activation Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical group C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Inorganic materials [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000000093 cytochemical effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000028315 developmental maturation Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000487 effect on differentiation Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108010038082 heparin proteoglycan Proteins 0.000 description 1
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000057877 human IGF2 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- XLTANAWLDBYGFU-UHFFFAOYSA-N methyllycaconitine hydrochloride Natural products C1CC(OC)C2(C3C4OC)C5CC(C(C6)OC)C(OC)C5C6(O)C4(O)C2N(CC)CC31COC(=O)C1=CC=CC=C1N1C(=O)CC(C)C1=O XLTANAWLDBYGFU-UHFFFAOYSA-N 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000005088 multinucleated cell Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 230000021268 myoblast fusion Effects 0.000 description 1
- 210000003365 myofibril Anatomy 0.000 description 1
- MQUQNUAYKLCRME-UHFFFAOYSA-N n-(4-chloro-3-oxo-1-phenylbutan-2-yl)-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-UHFFFAOYSA-N 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 229940100656 nasal solution Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 108010005636 polypeptide C Proteins 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 210000001883 posterior pituitary gland Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000007832 reinnervation Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 101150012509 sub gene Proteins 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- WQEVDHBJGNOKKO-UHFFFAOYSA-K vanadic acid Chemical compound O[V](O)(O)=O WQEVDHBJGNOKKO-UHFFFAOYSA-K 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- LYTCVQQGCSNFJU-LKGYBJPKSA-N α-bungarotoxin Chemical compound C(/[C@H]1O[C@H]2C[C@H]3O[C@@H](CC(=C)C=O)C[C@H](O)[C@]3(C)O[C@@H]2C[C@@H]1O[C@@H]1C2)=C/C[C@]1(C)O[C@H]1[C@@]2(C)O[C@]2(C)CC[C@@H]3O[C@@H]4C[C@]5(C)O[C@@H]6C(C)=CC(=O)O[C@H]6C[C@H]5O[C@H]4C[C@@H](C)[C@H]3O[C@H]2C1 LYTCVQQGCSNFJU-LKGYBJPKSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、1 992年11月6日にA.T.C.C.に寄託されたpGGF2HBS5(A. T.C.C.寄託番号75347)によってコードされるポリペプチドを薬学的 担体と混合することからなる方法。 2.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、E 配列(配列番号133および159)によってコードされるポリペプチドおよび 1992年11月6日にA.T.C.C.に寄託されたクローンpGGF2HB S5(A.T.C.C.寄託番号75347)に配列をコードするEをフランキ ングするDNA配列によってコードされるペプチドの少なくとも一部分を混合す ることからなる方法。 3.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、式 YBAZCX (式中、YBAZCXは図30に示されるポリペプチドセグメント(配列番号 133〜135、156、159)から構成され、式中、Yはポリペプチドセグ メントEからなるかまたは存在せず、式中、ZはポリペプチドセグメントGから なるかまたは存在せず、そして式中、XはポリペプチドセグメントC/D HK L、C/D H、C/D HL、C/D D、C/D′ HL、C/D′ HK L、C/D′ H、C/D′ D、C/D C/D′ HKL、C/D C/D ′ H、C/D C/D′ HL、C/D C/D′ D、C/D D′ H、C/ D D′ HL、C/D D′ HKL、C/D′ D′ H、C/D′ D′ HL、C/D′ D′ HKL、C/D C/D′ D′ H、C/D C/ D′ D′ HL、またはC/D C/D′ D′ HKLからなる)によって 定義されるポリペプチドを薬学的担体と混合することからなる方法。 4.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、式 WBAZCX (式中、WBAZCXは図30に示されるポリペプチドセグメント(配列番号 132、134、135、137〜139、156)から構成され、式中、Wは ポリペプチドセグメントFからなるかまたは存在せず、式中、Zはポリペプチド セグメントGからなるかまたは存在せず、そして式中、Xはポリペプチドセグメ ントC/D HKL、C/D H、C/D HL、C/D D、C/D′ HL 、C/D′ HKL、C/D′ H、C/D′ D、C/D C/D′ HKL 、C/D C/D′ H、C/D C/D′ HL、C/D C/D′ D、C /D D′ H、C/D D′ HL、C/D D′ HKL、C/D′ D′ H、C/D′ D′ HL、C/D′ D′ HKL、C/D C/D′ D ′ H、C/D C/D′ D′ HL、またはC/D C/D′ D′ HK Lからなる)によって定義されるポリペプチドを薬学的担体と混合することから なる方法。 5.50 N−末端アミノ酸が、E配列(配列番号133および159)からな る前記ペプチドから開裂される請求の範囲第1〜3項のいずれか1つに記載の方 法。 6.XがC/D HKLである請求の範囲第3項または第4項記載の方法。 7.XがC/D Hである請求の範囲第3項または第4項記載の方法。 8.XがC/D HLである請求の範囲第3項または第4項記載の方法。 9.XがC/D Dである請求の範囲第3項または第4項記載の方法。 10.XがC/D′ HLである請求の範囲第3項または第4項記載の方法。 11.XがC/D′ HKLである請求の範囲第3項または第4項記載の方法。 12.XがC/D′ Hである請求の範囲第3項または第4項記載の方法。 13.XがC/D′ Dである請求の範囲第3項または第4項記載の方法。 14.XがC/D C/D′ HKLである請求の範囲第3項または第4項記載の 方法。 15.XがC/D C/D′ Hである請求の範囲第3項または第4項記載の方法 。 16.XがC/D C/D′ HLである請求の範囲第3項または第4項記載の方 法。 17.XがC/D C/D′ Dである請求の範囲第3項または第4項記載の方法 。 18.XがC/D D′ Hである請求の範囲第3項また は第4項記載の方法。 19.XがC/D D′ HLである請求の範囲第3項または第4項記載の方法。 20.XがC/D D′ HKLである請求の範囲第3項または第4項記載の方法 。 21.XがC/D′ D′ Hである請求の範囲第3項または第4項記載の方法。 22.XがC/D′ D′ HLである請求の範囲第3項または第4項記載の方法 。 23.XがC/D′ D′ HKLである請求の範囲第3項または第4項記載の方 法。 24.XがC/D C/D′ D′ Hである請求の範囲第3項または第4項記載 の方法。 25.XがC/D C/D′ D′ HLである請求の範囲第3項または第4項記 載の方法。 26.XがC/D C/D′ D′ HKLである請求の範囲第3項または第4項 記載の方法。 27.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、図 30に示されるアミノ酸配列(配列番号132、134、135)を有するFBA ポリペプチドセグメントからなるポリペプチドを薬学的に許容しうる担体と混合 することからなる方法。 28.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、図 30に示されるアミノ酸配列(配列番号132、134、136)を有するFBA ′ポリペプチドセグメントからなるポリペプチドを薬学的に許容しうる担体と混 合することからなる方法。 29.ホ乳動物の筋細胞の治療のための医薬品の製造方法 であって、該方法が、図30に示されるアミノ酸配列(配列番号132、135 、159)を有するFEBAポリペプチドセグメントからなるポリペプチドを薬 学的に許容しうる担体と混合することからなる方法。 30.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、筋 細胞に対する図30に示されるポリペプチドセグメントに対応するアミノ酸配列 (配列番号132〜134、136、159)を有するFEBA′ポリペプチドセ グメントからなるポリペプチドを薬学的に許容しうる担体と混合することからな る方法。 31.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、G GF2ポリペプチドを薬学的に許容しうる担体と混合することからなる方法。 32.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、筋 細胞のp185erbB2受容体と特異的に結合する化合物を薬学的に許容しうる担 体と混合することからなる方法。 33.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、図 37に示されるアミノ酸配列、配列番号150、を有するEGFL1からなるポ リペプチドを薬学的に許容しうる担体と混合することからなる方法。 34.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、図 38に示されるアミノ酸配列、配列番号151、を有するEGFL2からなるポ リペプチドを薬学的に許容しうる担体と混合することからなる方法。 35.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、図 39に示されるアミノ酸配列、配列番号152、を有するEGFL3からなるポ リペプチドを薬学的に許容しうる担体と混合することからなる方法。 36.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、図 40に示されるアミノ酸配列、配列番号153、を有するEGFL4からなるポ リペプチドを薬学的に許容しうる担体と混合することからなる方法。 37.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、図 41に示されるアミノ酸配列、配列番号154、を有するEGFL5からなるポ リペプチドを薬学的に許容しうる担体と混合することからなる方法。 38.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、図 42に示されるアミノ酸配列、配列番号155、を有するEGFL6からなるポ リペプチドを薬学的に許容しうる担体と混合することからなる方法。 39.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、該 筋細胞に対するラットI−EJ形質転換された線維芽細胞系から単離された35 kDポリペプチド因子を、薬学的に許容しうる担体と混合することからなる方法 。 40.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、該 筋細胞に対するSKBR−3 ヒト胸部細胞系から単離された75kDポリペプ チ ド因子を、薬学的に許容しうる担体と混合することからなる方法。 41.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、該 筋細胞に対するラットI−EJ形質転換された線維芽細胞系から単離された44 kDポリペプチド因子を、薬学的に許容しうる担体と混合することからなる方法 。 42.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、該 筋細胞に対するMDA−MB231 ヒト胸部細胞系から単離された45kDポ リペプチド因子を、薬学的に許容しうる担体と混合することからなる方法。 43.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、該 筋細胞に対するATL−2ヒトT細胞系から単離された7〜14kDポリペプチ ド因子を、薬学的に許容しうる担体と混合することからなる方法。 44.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、該 筋細胞に対する活性化されたマウス腹腔マクロファージから単離された25kD ポリペプチド因子を、薬学的に許容しうる担体と混合することからなる方法。 45.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、該 筋細胞に対するウシ腎臓から単離された25kDポリペプチド因子を、薬学的に 許容しうる担体と混合することからなる方法。 46.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、該 筋細胞に対するARIAポリ ペプチドを、薬学的に許容しうる担体と混合することからなる方法。 47.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、該 筋細胞に対する0〜2A前グリア細胞を刺激する46〜47kDポリペプチド因 子を薬学的に許容しうる担体と混合することからなる方法。 48.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、該 筋細胞に対するGGF−IIIを、薬学的に許容しうる担体と混合することからな る方法。 49.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、発 現可能な遺伝子構造にある、式 YBAZCX (式中、YBAZCXは図30に示されるポリペプチドセグメント(配列番号 133〜135、156、159)から構成され、式中、Yはポリペプチドセグ メントEからなるかまたは存在せず、式中、ZはポリペプチドセグメントGから なるかまたは存在せず、そして式中、XはポリペプチドセグメントC/D HK L、C/D H、C/D HL、C/D D、C/D′ HL、C/D′ HK L、C/D′ H、C/D′ D、C/D C/D′ HKL、C/D C/D ′ H、C/D C/D′ HL、C/D C/D′ D、C/D D′ H、 C/D D′ HL、C/D D′ HKL、C/D′ D′ H、C/D′ D′ HL、C/D′ D′ HKL、C/D C/D′ D′ H、C/D C/D′ D′ HL、または C/D C/D′ D′ HKLからなる)を有するポリペプチドをコードする DNA配列を、薬学的に許容しうる担体と混合することからなる方法。 50.ホ乳動物の筋細胞の治療のための医薬品の製造方法であって、該方法が、発 現可能な遺伝子構築物にある、式 WBAZCX (式中、WBAZCXは図30に示されるポリペプチドセグメント(配列番号 132、134、135、137〜139、156)から構成され、式中、Wは ポリペプチドセグメントFからなるかまたは存在せず、式中、Zはポリペプチド セグメントGからなるかまたは存在せず、そして式中、Xはポリペプチドセグメ ントC/D HKL、C/D H、C/D HL、C/D D、C/D′ HL 、C/D′ HKL、C/D′ H、C/D′ D、C/D C/D′ HKL 、C/D C/D′ H、C/D C/D′ HL、C/D C/D′ D、C /D D′ H、C/D D′ HL、C/D D′ HKL、C/D′ D′ H、C/D′ D′ HL、C/D′ D′ HKL、C/D C/D′ D ′ H、C/D C/D′ D′ HL、またはC/D C/D′ D′ HK Lからなる)を有するポリペプチドをコードするDNA配列を、薬学的に許容し うる担体と混合することからなる方法。 51.ホ乳動物の筋組織の病理学的コンディションの予防または治療のための医薬 品の製造方法であって、該コンディションが、請求の範囲第1、3、4および 31項のいずれか1つに定義されたポリペプチドに対して感受性であるかまたは 反応性である筋細胞タイプを含み、 該方法が、有効量の該ポリペプチドを薬学的に許容しうる担体と混合すること からなる方法。 52.ホ乳動物の筋ダメージを含むコンディションの治療のための医薬品の製造方 法であって、該方法が請求の範囲第1、3、4および31項のいずれか1つに定 義された、有効量のポリペプチドを薬学的に許容しうる担体と混合することから なる方法。 53.前記医薬品が、前記筋細胞の萎縮を減少させるためのものである、請求の範 囲第1、3、4および31項のいずれか1つに記載の方法。 54.前記医薬品が、前記ホ乳動物に存在する筋線維を増加させるためのものであ る、請求の範囲第1、3、4および31項のいずれか1つに記載の方法。 55.前記医薬品が、前記ホ乳動物に生存する筋細胞を増加させるためのものであ る、請求の範囲第1、3、4および31項のいずれか1つに記載の方法。 56.前記医薬品が、前記ホ乳動物での筋増殖を増進させるためのものである、請 求の範囲第1、3、4および31項のいずれか1つに記載の方法。 57.前記医薬品が、前記ホ乳動物での筋再生を増進させるためのものである、請 求の範囲第1、3、4および31項のいずれか1つに記載の方法。 58.前記医薬品が、筋細胞の分裂促進を刺激するためのものである、請求の範囲 第1、3、4および31項のいずれか1つに記載の方法。 59.前記医薬品が、アセチルコリン受容体の合成を増進させるためのものである 、請求の範囲第1、3、4および31項のいずれか1つに記載の方法。 60.前記医薬品が、神経親和性因子を欠く患者の治療用である、請求の範囲第1 、3、4および31項のいずれか1つに記載の方法。 61.前記医薬品が、筋芽細胞である筋細胞の治療用である、請求の範囲第1、3 、4および31項のいずれか1つに記載の方法。 62.前記医薬品が、付随細胞である筋細胞の治療用である、請求の範囲第1、3 、4および31項のいずれか1つに記載の方法。 63.前記医薬品が、骨格筋の筋細胞の治療用である、請求の範囲第1、3、4お よび31項のいずれか1つに記載の方法。 64.前記医薬品が、心筋の筋細胞の治療用である、請求の範囲第1、3、4およ び31項のいずれか1つに記載の方法。 65.前記医薬品が、平滑筋の筋細胞の治療用である、請求の範囲第1、3、4お よび31項のいずれか1つに記載の方法。 66.前記医薬品が、骨格筋疾患を有する患者の筋細胞の治療用である、請求の範 囲第1、3、4および31項のいずれか1つに記載の方法。 67.前記骨格筋疾患がミオパシーである請求の範囲第66項記載の方法。 68.前記骨格筋疾患がジストロフィーである請求の範囲第66項記載の方法。 69.前記ジストロフィーがデュシェーヌ型筋ジストロフィーである請求の範囲第 68項記載の方法。 70.前記ジストロフィーがベッカー型ジストロフィーである請求の範囲第68項 記載の方法。 71.前記骨格筋疾患が神経コンディションに起因する請求の範囲第66項記載の 方法。 72.前記骨格筋疾患が損傷である請求の範囲第66項記載の方法。 73.前記骨格筋疾患が神経損傷に起因する請求の範囲第66項記載の方法。 74.前記骨格筋疾患がニューロパシーに起因する請求の範囲第66項記載の方法 。 75.前記医薬品が、心筋障害を有する患者の筋細胞の治療用である、請求の範囲 第1、3、4および31項のいずれか1つに記載の方法。 76.前記心障害が心筋症である請求の範囲第75項記載の方法。 77.前記心障害が虚血性ダメージである請求の範囲第75項記載の方法。 78.前記心障害が先天性疾患である請求の範囲第75項記載の方法。 79.前記心障害が心臓の外傷である請求の範囲第75項記載の方法。 80.前記医薬品が平滑筋障害を有する患者の筋細胞の治療用である、請求の範囲 第1、3、4および31項のいずれか1つに記載の方法。 81.前記障害が動脈硬化である請求の範囲第80項記載の方法。 82.前記障害が血管障害である請求の範囲第80項記載の方法。 83.前記障害が先天性血管疾患である請求の範囲第80項記載の方法。 84.前記医薬品が、機能不全なアセチルコリン受容体を有する筋細胞の治療用で ある、請求の範囲第1、3、4および31項のいずれか1つに記載の方法。 85.充分なアセチルコリン受容体を欠く前記筋細胞が、重症筋無力症の患者の筋 細胞である請求の範囲第85項記載の方法。 86.前記コンディションが筋ダメージを含む請求の範囲第84項記載の方法。 87.患者の筋腫瘍の予防または治療のための医薬品の製造方法であって、該方法 が、 請求の範囲第1、3、4および31項のいずれか1つに定義された因子のその 受容体への結合を阻害する有効量の物質を、薬学的に許容しうる担体と混合する こと からなる方法。 88.筋細胞増殖の疾患を患うホ乳動物を治療するための医薬品の製造方法であっ て、該方法が、 請求の範囲第1、3、4および31項のいずれか1つに記載のポリペプチドと 結合する抗体を、薬学的に許容しうる担体と混合すること からなる方法。 89.筋細胞の分裂促進活性を有する分子をコードする核酸配列を同定する方法で あって、該方法が、 サンプルを含有する細胞と、該筋細胞分裂促進剤に特 異的な抗体とを接触させて該サンプル中の筋細胞分裂促進剤の発現を測定するこ と、および 該発現を示す細胞から該核酸配列を単離すること からなる方法。 90.前記GGF2がヒト組換えGGF2である請求の範囲第31項記載の方法。 91.筋細胞の筋発生を刺激する方法であって、該方法が、該筋細胞と、筋細胞の p185erbB2受容体に特異的に結合する化合物とを接触させることからなる方 法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5902293A | 1993-05-06 | 1993-05-06 | |
US08/059,022 | 1993-05-06 | ||
US08/209,204 US7115554B1 (en) | 1993-05-06 | 1994-03-08 | Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III |
US08/209,204 | 1994-03-08 | ||
PCT/US1994/005083 WO1994026298A1 (en) | 1993-05-06 | 1994-05-06 | Methods for treating muscle diseases and disorders |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003125885A Division JP4018028B2 (ja) | 1993-05-06 | 2003-04-30 | 筋肉の疾患または障害の治療または予防のための医薬品 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11507201A true JPH11507201A (ja) | 1999-06-29 |
JP4035159B2 JP4035159B2 (ja) | 2008-01-16 |
Family
ID=26738273
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52559394A Expired - Lifetime JP4035159B2 (ja) | 1993-05-06 | 1994-05-06 | 筋肉の疾患および障害の治療方法 |
JP2003125885A Expired - Lifetime JP4018028B2 (ja) | 1993-05-06 | 2003-04-30 | 筋肉の疾患または障害の治療または予防のための医薬品 |
JP2007203508A Pending JP2007332153A (ja) | 1993-05-06 | 2007-08-03 | 筋肉の疾患または障害の治療または予防のための医薬品 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003125885A Expired - Lifetime JP4018028B2 (ja) | 1993-05-06 | 2003-04-30 | 筋肉の疾患または障害の治療または予防のための医薬品 |
JP2007203508A Pending JP2007332153A (ja) | 1993-05-06 | 2007-08-03 | 筋肉の疾患または障害の治療または予防のための医薬品 |
Country Status (10)
Country | Link |
---|---|
US (5) | US7115554B1 (ja) |
EP (1) | EP0703785B8 (ja) |
JP (3) | JP4035159B2 (ja) |
KR (2) | KR100284909B1 (ja) |
AT (1) | ATE299710T1 (ja) |
AU (1) | AU691810B2 (ja) |
CA (1) | CA2162262C (ja) |
DE (1) | DE69434431T2 (ja) |
ES (1) | ES2243928T3 (ja) |
WO (1) | WO1994026298A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001083705A1 (fr) * | 2000-04-27 | 2001-11-08 | Kyowa Hakko Kogyo Co., Ltd. | Genes associes a la proliferation de cellules myocardiques |
JP2014122923A (ja) * | 2007-05-10 | 2014-07-03 | Acorda Therapeutics Inc | 心臓障害を検出するための方法 |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115554B1 (en) * | 1993-05-06 | 2006-10-03 | Acorda Therapeutics, Inc. | Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III |
US7037888B1 (en) * | 1992-04-03 | 2006-05-02 | Acorda Therapeutics, Inc. | Methods for treating muscle diseases and disorders |
FR2731225B1 (fr) * | 1995-03-03 | 2003-10-31 | Pasteur Institut | Peptides de glycoproteine transmembranaire d'enveloppe et de proteine de capside du retrovirus humain du type hiv-1 et peptides presentant avec eux une parente immunologique |
CN102134609A (zh) | 1994-10-20 | 2011-07-27 | 巴斯德研究所 | Hiv-1 o组(或亚组)逆转录病毒抗原的核苷酸序列 |
AU727606B2 (en) | 1996-07-12 | 2000-12-14 | Genentech Inc. | Gamma-heregulin |
US6387638B1 (en) | 1997-02-10 | 2002-05-14 | Genentech, Inc. | Heregulin variants |
US6136558A (en) * | 1997-02-10 | 2000-10-24 | Genentech, Inc. | Heregulin variants |
US20010023241A1 (en) | 1998-02-04 | 2001-09-20 | Sliwkowski Mark X. | Use of heregulin as a growth factor |
AU1649400A (en) * | 1998-12-11 | 2000-07-03 | Tejvir S. Khurana | Neurite derived growth factors for use in the treatment of muscular dystrophy |
AUPP785098A0 (en) * | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
US6967102B1 (en) * | 1999-03-11 | 2005-11-22 | University Of Manitoba | Nitric oxide manipulation of muscle satellite cell activation |
US6635249B1 (en) | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
US7495147B2 (en) | 2000-02-28 | 2009-02-24 | Decode Genetics Ehf. | Neuregulin-1 transgenic mouse and methods of use |
JP5324732B2 (ja) * | 2000-05-23 | 2013-10-23 | スネス ファーマシューティカルズ インコーポレイテッド | Nrg−2核酸分子、ポリペプチド、ならびに診断および治療法 |
AU2002304965A1 (en) | 2002-05-24 | 2003-12-12 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
AU2003272805A1 (en) * | 2002-10-01 | 2004-04-23 | Peter K. Law | Bioactive implants |
US20070213264A1 (en) | 2005-12-02 | 2007-09-13 | Mingdong Zhou | Neuregulin variants and methods of screening and using thereof |
JP5738516B2 (ja) | 2005-12-30 | 2015-06-24 | ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド | 心機能改善のためのニューレグリンの徐放 |
EP2117582B1 (en) * | 2007-01-22 | 2013-06-26 | Children's Medical Center Corporation | Periostin induces proliferation of cardiomyocytes and promotes cardiac regeneration |
US8354446B2 (en) | 2007-12-21 | 2013-01-15 | Ligand Pharmaceuticals Incorporated | Selective androgen receptor modulators (SARMs) and uses thereof |
JP5797112B2 (ja) | 2008-07-17 | 2015-10-21 | アコーダ セラピューティクス インコーポレイテッド | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
CN104707130A (zh) | 2008-08-15 | 2015-06-17 | 阿索尔达治疗公司 | 在cns神经性损伤后非-急性期间处理的组合物及方法 |
JP5743898B2 (ja) | 2008-11-28 | 2015-07-01 | ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド | ニューレグリンペプチド及びその使用 |
WO2011011388A2 (en) * | 2009-07-22 | 2011-01-27 | Children's Medical Center Corporation | Neuregulin induced regeneraton of heart muscle muscle |
EP2575862A2 (en) * | 2010-05-28 | 2013-04-10 | Mind-Nrg Sa | Neuregulin isoforms, neuregulin polypeptides and uses thereof |
WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun (Shanghai)Science & Technology Limited | Compositions and methods for treating heart failure |
EP3895724A1 (en) | 2013-05-22 | 2021-10-20 | Zensun (Shanghai) Science and Technology, Co., Ltd. | Extended release of neuregulin for treating heart failure |
KR102051433B1 (ko) * | 2013-08-27 | 2020-01-08 | (주)네오팜 | 근육 분화 촉진 및 근육 강화용 조성물 및 외용제 |
CN104758922A (zh) | 2014-01-03 | 2015-07-08 | 上海泽生科技开发有限公司 | 纽兰格林制剂的配方 |
EP3613418A1 (en) | 2014-01-17 | 2020-02-26 | Ligand Pharmaceuticals, Inc. | Methods and compositions for modulating hormone levels |
CN105497876B (zh) | 2014-09-24 | 2021-01-15 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物 |
CN111407882A (zh) | 2014-10-17 | 2020-07-14 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
AR121035A1 (es) | 2019-04-01 | 2022-04-13 | Lilly Co Eli | Compuestos de neuregulina-4 y métodos de uso |
AU2020348436A1 (en) | 2019-09-16 | 2022-04-07 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Recombinant human neuregulin derivatives and use thereof |
CN113289002A (zh) | 2020-02-24 | 2021-08-24 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物 |
US20220402985A1 (en) | 2021-06-10 | 2022-12-22 | Amgen Inc. | ENGINEERED NRG-1 VARIANTS WITH IMPROVED SELECTIVITY TOWARD ErbB4 BUT NOT AGAINST ErbB3 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4935341A (en) | 1986-06-04 | 1990-06-19 | Whitehead Institute For Biomedical Research | Detection of point mutations in neu genes |
US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US5143842A (en) * | 1988-11-01 | 1992-09-01 | The University Of Colorado Foundation, Inc. | Media for normal human muscle satellite cells |
WO1990014357A1 (en) | 1989-05-19 | 1990-11-29 | Genentech, Inc. | Her2 extracellular domain |
US5464751A (en) | 1990-04-06 | 1995-11-07 | Trustees Of The University Of Pennsylvania | Ligand for the neu gene product |
EP0597845A1 (en) | 1990-05-25 | 1994-05-25 | Georgetown University | GROWTH FACTOR WHICH INHIBITS THE GROWTH OF CELLS OVEREXPRESSING THE HUMAN ONCOGENE erbB-2 |
WO1992000329A1 (en) | 1990-06-27 | 1992-01-09 | Biogen, Inc. | Surface complexed lymphotoxin |
DE69229597D1 (de) | 1991-01-14 | 1999-08-19 | Univ Georgetown | Wachstumsfaktor-ligand, der an den erbb-2-rezeptor bindet und die zellulären reaktionen induziert |
US5530109A (en) | 1991-04-10 | 1996-06-25 | Ludwig Institute For Cancer Research | DNA encoding glial mitogenic factors |
US7115554B1 (en) * | 1993-05-06 | 2006-10-03 | Acorda Therapeutics, Inc. | Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III |
US5367060A (en) | 1991-05-24 | 1994-11-22 | Genentech, Inc. | Structure, production and use of heregulin |
GB9217316D0 (en) * | 1992-08-14 | 1992-09-30 | Ludwig Inst Cancer Res | Schwann cell mitogenic factor,its preparation and use |
US6635249B1 (en) * | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
-
1994
- 1994-03-08 US US08/209,204 patent/US7115554B1/en not_active Expired - Lifetime
- 1994-05-06 KR KR1019950704903A patent/KR100284909B1/ko not_active IP Right Cessation
- 1994-05-06 CA CA2162262A patent/CA2162262C/en not_active Expired - Lifetime
- 1994-05-06 ES ES94916690T patent/ES2243928T3/es not_active Expired - Lifetime
- 1994-05-06 WO PCT/US1994/005083 patent/WO1994026298A1/en active IP Right Grant
- 1994-05-06 AU AU68278/94A patent/AU691810B2/en not_active Expired
- 1994-05-06 EP EP94916690A patent/EP0703785B8/en not_active Expired - Lifetime
- 1994-05-06 AT AT94916690T patent/ATE299710T1/de not_active IP Right Cessation
- 1994-05-06 JP JP52559394A patent/JP4035159B2/ja not_active Expired - Lifetime
- 1994-05-06 DE DE69434431T patent/DE69434431T2/de not_active Expired - Lifetime
-
1995
- 1995-06-06 US US08/468,731 patent/US7384756B1/en active Active
- 1995-06-06 US US08/467,602 patent/US6444642B1/en not_active Expired - Lifetime
-
2000
- 2000-09-14 KR KR1020000054080A patent/KR100306244B1/ko not_active IP Right Cessation
-
2003
- 2003-04-30 JP JP2003125885A patent/JP4018028B2/ja not_active Expired - Lifetime
-
2007
- 2007-08-03 JP JP2007203508A patent/JP2007332153A/ja active Pending
-
2008
- 2008-06-10 US US12/157,614 patent/US7718606B2/en not_active Expired - Fee Related
-
2010
- 2010-05-17 US US12/781,633 patent/US8026213B2/en not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001083705A1 (fr) * | 2000-04-27 | 2001-11-08 | Kyowa Hakko Kogyo Co., Ltd. | Genes associes a la proliferation de cellules myocardiques |
JP2014122923A (ja) * | 2007-05-10 | 2014-07-03 | Acorda Therapeutics Inc | 心臓障害を検出するための方法 |
JP2017026622A (ja) * | 2007-05-10 | 2017-02-02 | アコーダ セラピューティクス インコーポレイテッド | 心臓障害を検出するための方法 |
Also Published As
Publication number | Publication date |
---|---|
US8026213B2 (en) | 2011-09-27 |
ATE299710T1 (de) | 2005-08-15 |
EP0703785A4 (en) | 1998-12-30 |
AU691810B2 (en) | 1998-05-28 |
EP0703785B1 (en) | 2005-07-20 |
CA2162262C (en) | 2011-07-12 |
EP0703785A1 (en) | 1996-04-03 |
JP2004043437A (ja) | 2004-02-12 |
CA2162262A1 (en) | 1994-11-24 |
US20090018073A1 (en) | 2009-01-15 |
US7718606B2 (en) | 2010-05-18 |
WO1994026298A1 (en) | 1994-11-24 |
EP0703785B8 (en) | 2005-09-14 |
ES2243928T3 (es) | 2005-12-01 |
JP2007332153A (ja) | 2007-12-27 |
KR960702318A (ko) | 1996-04-27 |
AU6827894A (en) | 1994-12-12 |
KR100284909B1 (ko) | 2001-03-15 |
US7115554B1 (en) | 2006-10-03 |
US7384756B1 (en) | 2008-06-10 |
JP4018028B2 (ja) | 2007-12-05 |
US6444642B1 (en) | 2002-09-03 |
DE69434431D1 (de) | 2005-08-25 |
JP4035159B2 (ja) | 2008-01-16 |
US20110144015A1 (en) | 2011-06-16 |
DE69434431T2 (de) | 2006-05-24 |
KR100306244B1 (ko) | 2001-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4035159B2 (ja) | 筋肉の疾患および障害の治療方法 | |
EP0653940B1 (en) | Glial mitogenic factors, their preparation and use | |
US5716930A (en) | Glial growth factors | |
WO1994026298A9 (en) | Methods for treating muscle diseases and disorders | |
US7037888B1 (en) | Methods for treating muscle diseases and disorders | |
AU693767B2 (en) | Inhibitors of cell proliferation, their preparation and use | |
US20090246867A1 (en) | Glial mitogenic factors, their preparation and use | |
US7541338B2 (en) | Glial mitogenic factors, their preparation and use | |
US7135456B1 (en) | Glial mitogenic factors, their preparation and use | |
US7094749B1 (en) | Glial mitogenic factors, their preparation and use | |
US20050106666A1 (en) | Glial mitogenic factors, their preparation and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051213 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060313 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070306 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070605 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070723 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070704 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070820 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070803 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20071009 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20071029 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101102 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111102 Year of fee payment: 4 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111102 Year of fee payment: 4 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111102 Year of fee payment: 4 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111102 Year of fee payment: 4 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121102 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121102 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131102 Year of fee payment: 6 |
|
EXPY | Cancellation because of completion of term |